OSE Immuno - H1 update
*Last night, OSE Immuno provided an H1 update, most notably announcing/reiterating 1/ cash runway until Q4 2024, 2/ Ph2 ulcerative colitis (UC) results in the next few months, and 3/ launch of the confirmatory Ph3 for Tedopi in 2024.*Overall, we consider the update rather light in content; the company has taken the necessary measures to extent its runway in order to advance Lusvertikimab for UC and its research programs but we still remain in the dark regarding the financing/partnering strategy fort the confirmatory Ph3.*Following this H1 update, we have pushed clinical development timelines for Tedopi and FR104, and updated ourOse Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.